Education
About Us
Working with TipRanks
Follow Us
Boston Scientific (BSX)
NYSE:BSX
BSX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$71.88 - $107.53
Previous CloseN/A
Volume5.49M
Average Volume (3M)7.43M
Market Cap
$154.34B
Enterprise Value$165.32B
Total Cash (Recent Filing)$725.00M
Total Debt (Recent Filing)$11.71B
Price to Earnings (P/E)76.4
Beta0.83
Next Earnings
Jul 23, 2025EPS Estimate
0.73Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.75
Shares Outstanding1,479,446,300
10 Day Avg. Volume7,608,821
30 Day Avg. Volume7,430,294
Financial Highlights & Ratios
PEG Ratio7.96
Price to Book (P/B)6.94
Price to Sales (P/S)0.00
P/FCF Ratio53.72
Enterprise Value/Market Cap1.07
Enterprise Value/Revenue2.53
Enterprise Value/Gross Profit13.72
Enterprise Value/Ebitda10.78
Forecast
1Y Price Target
$119.57Price Target Upside14.62% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
Boston Scientific News
Bulls Say, Bears Say
Bulls Say
Innovation And Market PositionBoston Scientific is very well-positioned to deliver above-consensus results in its Electrophysiology and Watchman businesses, driven by the highly attractive growth dynamics of these end markets.
Market LeadershipBoston Scientific's Watchman Left Atrial Appendage Closure device holds a 90% share of its market, benefiting from more time before facing competition from JNJ.
Revenue GrowthAnalyst maintains a Buy rating on Boston Scientific due to a durable double-digit revenue growth outlook with high margin revenue potential.
Bears Say
Clinical Trial DelaysThe IDE study evaluating the LAMINAR Left Atrial Appendage Elimination device was voluntarily paused due to issues with unwrapping, leading to leaks in select device sizes.
Revenue ImpactThe loss of approximately $200 million ACURATE OUS revenue is about a 1-point impact to Boston Scientific's growth rate.
Ownership Overview
0.16% Insiders
30.06% Mutual Funds
18.84% Other Institutional Investors
28.76% Public Companies and Individual Investors
BSX FAQ
What was Boston Scientific’s price range in the past 12 months?
Boston Scientific lowest stock price was $71.88 and its highest was $107.53 in the past 12 months.
What is Boston Scientific’s market cap?
Boston Scientific’s market cap is $154.34B.
When is Boston Scientific’s upcoming earnings report date?
Boston Scientific’s upcoming earnings report date is Jul 23, 2025 which is in 16 days.
How were Boston Scientific’s earnings last quarter?
Boston Scientific released its earnings results on Apr 23, 2025. The company reported $0.75 earnings per share for the quarter, beating the consensus estimate of $0.673 by $0.077.
Is Boston Scientific overvalued?
According to Wall Street analysts Boston Scientific’s price is currently Undervalued.
Does Boston Scientific pay dividends?
Boston Scientific does not currently pay dividends.
What is Boston Scientific’s EPS estimate?
Boston Scientific’s EPS estimate is 0.73.
How many shares outstanding does Boston Scientific have?
Boston Scientific has 1,479,446,300 shares outstanding.
What happened to Boston Scientific’s price movement after its last earnings report?
Boston Scientific reported an EPS of $0.75 in its last earnings report, beating expectations of $0.673. Following the earnings report the stock price went up 4.072%.
Which hedge fund is a major shareholder of Boston Scientific?
Currently, no hedge funds are holding shares in BSX
Boston Scientific Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$119.57 (14.62% Upside)
$119.57 (14.62% Upside)
Blogger Sentiment
Bullish
BSX Sentiment 73%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 892.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $418.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 4.8%
Last 30 Days ▲ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.06%
12-Months-Change
Fundamentals
Return on Equity
9.65%
Trailing 12-Months
Asset Growth
9.47%
Trailing 12-Months
Company Description
Boston Scientific
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
BSX Company Deck
BSX Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected a generally positive outlook with strong revenue and EPS growth exceeding expectations, particularly in the cardiology and electrophysiology segments. However, challenges such as significant tariff impacts, slower growth in certain segments, and foreign exchange headwinds were noted, adding some concerns to the otherwise strong performance.Read More>BSX Revenue Breakdown
64.22% Cardiovascular
35.79% MedSurg
BSX Stock 12 Month Forecast
Average Price Target
$119.57
▲(14.62%Upside)